Cochrane Abstracts
Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Capecitabine for Hormone Receptor‐positive Versus Hormone Receptor‐negative Breast Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Capecitabine_for_hormone_receptor‐positive_versus_hormone_receptor‐negative_breast_cancer.
Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Capecitabine_for_hormone_receptor‐positive_versus_hormone_receptor‐negative_breast_cancer. Accessed March 25, 2025.
Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Capecitabine_for_hormone_receptor‐positive_versus_hormone_receptor‐negative_breast_cancer
Capecitabine for Hormone Receptor‐positive Versus Hormone Receptor‐negative Breast Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 25]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Capecitabine_for_hormone_receptor‐positive_versus_hormone_receptor‐negative_breast_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer
ID - 438840
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Capecitabine_for_hormone_receptor‐positive_versus_hormone_receptor‐negative_breast_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
